XTL Biopharmaceuticals Ltd.(XTLB)Earnings, Financials & Key Ratios

XTLB•NASDAQ

$3.66

$402692 mkt cap·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryImmunology and Inflammation Therapies

AboutXTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.Show more

Revenue$451K
EBITDA-$2M-158.2%
Net Income-$1M-57531.9%
EPS (Diluted)-9.60
Gross Margin0.67%
EBITDA Margin-437.47%
Operating Margin-481.6%
Net Margin-227.72%
ROE-26.83%-46727.4%
ROIC-54.11%-28.5%
Debt/Equity0.03
Interest Coverage-13.13+93.1%

Technical→

XTLB Key Insights

XTL Biopharmaceuticals Ltd. (XTLB) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 29.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

XTLB Price & Volume

XTL Biopharmaceuticals Ltd. (XTLB) stock price & volume — 10-year historical chart

Loading chart...

XTLB Growth Metrics

XTL Biopharmaceuticals Ltd. (XTLB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM42.37%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM45.45%

Return on Capital

10 Years-31.57%

5 Years-24.59%

3 Years-30.76%

Last Year-50.73%

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
NRXPNRx Pharmaceuticals, Inc.Direct Competitor	84.15M	3.04	-2.27		-157.28%
SIGASIGA Technologies, Inc.Direct Competitor	332.28M	4.64	14.06	-31.8%	24.64%	0%	14.66%	0
BFRIBiofrontera Inc.Direct Competitor	13.4M	1.15		11.8%	-25.26%	-11.39%		0.59
AEYEAudioEye, Inc.Direct Competitor	93.6M	7.54	-30.16	14.52%	-7.63%	-47.8%		0.15
AVXLAnavex Life Sciences Corp.Product Competitor	311.38M	3.36	-6.22			-31.55%
INVAInnoviva, Inc.Product Competitor	1.69B	22.65	6.86	18.52%	65.38%	23.12%	11.58%
PRAXPraxis Precision Medicines, Inc.Product Competitor	7.5B	333.30	-24.73	-100%		-58.74%		0.00
ACADACADIA Pharmaceuticals Inc.Product Competitor	3.78B	22.35	16.43	31.85%	24.94%	28.47%	4.16%	0.07

Compare XTLB vs Peers

XTL Biopharmaceuticals Ltd. (XTLB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NRXP

Most directly comparable listed peer for XTLB.

Scale Benchmark

vs MEDP

Larger-name benchmark to compare XTLB against a more recognizable public peer.

Peer Set

Compare Top 5

vs NRXP, SIGA, BFRI, AEYE

XTLB Income Statement

XTL Biopharmaceuticals Ltd. (XTLB) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24
Sales/Revenue	0	0	0	0	0	0	0	0	451K
Revenue Growth %	-	-	-	-	-	-	-	-	-
Cost of Goods Sold	0	0	0	0	1K	1K	1K	0	448K
COGS % of Revenue	-	-	-	-	-	-	-	-	99.33%
Gross Profit	0▲ 0%	0▲ 0%	0▲ 0%	0▲ 0%	-1K▲ 0%	-1K▲ 0.0%	-1K▲ 0.0%	0▲ 100.0%	3K▲ 0%
Gross Margin %	-	-	-	-	-	-	-	-	0.67%
Gross Profit Growth %	-	-	-	-	-	0%	0%	100%	-
Operating Expenses	1.71M	1.25M	793K	842K	948K	1.03M	880K	765K	2.17M
OpEx % of Revenue	-	-	-	-	-	-	-	-	482.26%
Selling, General & Admin	1.26M	1.19M	755K	807K	910K	1M	850K	734K	2.05M
SG&A % of Revenue	-	-	-	-	-	-	-	-	453.66%
Research & Development	443K	43K	38K	35K	38K	30K	30K	31K	98K
R&D % of Revenue	-	-	-	-	-	-	-	-	21.73%
Other Operating Expenses	0	0	0	0	0	0	0	0	31K
Operating Income	-2.56M▲ 0%	-1.25M▲ 51.3%	-793K▲ 36.4%	-842K▼ 6.2%	-948K▼ 12.6%	-1.03M▼ 8.8%	-880K▲ 14.6%	-765K▲ 13.1%	-2.17M▼ 183.9%
Operating Margin %	-	-	-	-	-	-	-	-	-481.6%
Operating Income Growth %	29.08%	51.35%	36.36%	-6.18%	-12.59%	-8.76%	14.65%	13.07%	-183.92%
EBITDA	-2.56M	-1.25M	-792K	0	-947K	-1.03M	-879K	-764K	-1.97M
EBITDA Margin %	-	-	-	-	-	-	-	-	-437.47%
EBITDA Growth %	29.02%	51.33%	36.39%	100%	-	-8.76%	14.66%	13.08%	-158.25%
D&A (Non-Cash Add-back)	3K	1K	1K	842K	1K	1K	1K	1K	199K
EBIT	-1.71M	-1.25M	-793K	-842K	-948K	-1.03M	-880K	-765K	-1.13M
Net Interest Income	0	8K	80K	64K	16K	-13K	25K	37K	-52K
Interest Income	0	16K	87K	93K	33K	8K	36K	41K	34K
Interest Expense	0	8K	7K	29K	17K	21K	11K	4K	86K
Other Income/Expense	16K	465K	4.42M	79K	-2.01M	1.47M	-468K	-1.02M	1.01M
Pretax Income	-2.54M▲ 0%	-781K▲ 69.3%	2.99M▲ 482.3%	-1.35M▼ 145.1%	-2.95M▼ 119.3%	435K▲ 114.7%	-1.35M▼ 409.9%	-1.78M▼ 32.2%	-1.16M▲ 35.1%
Pretax Margin %	-	-	-	-	-	-	-	-	-256.54%
Income Tax	0	0	-80K	-69K	0	0	0	0	-130K
Effective Tax Rate %	0%	0%	-2.68%	5.12%	0%	0%	0%	0%	11.24%
Net Income	-2.54M▲ 0%	-781K▲ 69.3%	2.99M▲ 482.3%	-1.35M▼ 145.1%	-782K▲ 41.9%	435K▲ 155.6%	-1.35M▼ 409.9%	-1.78K▲ 99.9%	-1.03M▼ 57531.9%
Net Margin %	-	-	-	-	-	-	-	-	-227.72%
Net Income Growth %	40.97%	69.31%	482.33%	-145.11%	41.95%	155.63%	-409.89%	99.87%	-57531.87%
Net Income (Continuing)	-2.54M	-781K	3.63M	-763K	-2.95M	435K	-1.35M	-1.78M	-1.03M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-59.52▲ 0%	-10.88▲ 81.7%	37.12▲ 441.2%	-16.64▼ 144.8%	-36.48▼ 119.2%	4.48▲ 112.3%	-16.00▼ 457.1%	0.00▲ 100.0%	-9.60▲ 0%
EPS Growth %	42.94%	81.72%	441.18%	-144.83%	-119.23%	112.28%	-457.14%	100%	-
EPS (Basic)	-59.52	-10.88	37.12	-16.64	-36.48	5.12	-16.00	0.00	-9.60
Diluted Shares Outstanding	42.82K	73.47K	80.34K	80.34K	80.34K	96.18K	85.14K	85.14K	110.03K
Basic Shares Outstanding	42.82K	73.47K	80.34K	80.34K	80.34K	83.12K	85.17K	85.15K	105.16K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

XTLB Balance Sheet

XTL Biopharmaceuticals Ltd. (XTLB) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24
Total Current Assets	2.75M	6.21M	8.2M	6.83M	6.12M	6.24M	3.81M	2.05M	1.34M
Cash & Short-Term Investments	2.43M	6.09M	8.12M	6.73M	6.04M	6.13M	3.72M	2.01M	1.14M
Cash Only	2.02M	3.29M	3.25M	4.46M	3.63M	2.97M	2.09M	1.4M	371K
Short-Term Investments	414K	2.81M	4.87M	2.27M	2.41M	3.16M	1.63M	605K	772K
Accounts Receivable	12K	0	0	0	0	94K	71K	29K	99K
Days Sales Outstanding	-	-	-	-	-	-	-	-	80.12
Inventory	130K	85K	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	179K	0	0	20K	13K	-78K	-57K	-18K	47K
Total Non-Current Assets	263K	380K	380K	382K	382K	381K	380K	380K	7.21M
Property, Plant & Equipment	10K	0	0	2K	2K	1K	0	0	187K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	2.41x
Goodwill	0	0	0	0	0	0	0	0	3.19M
Intangible Assets	253K	380K	380K	380K	380K	380K	380K	380K	3.82M
Long-Term Investments	0	0	0	0	0	0	0	0	14K
Other Non-Current Assets	0	0	0	0	0	0	0	0	0
Total Assets	3.02M▲ 0%	6.59M▲ 118.3%	8.57M▲ 30.2%	7.21M▼ 15.9%	6.5M▼ 9.8%	6.62M▲ 1.8%	4.19M▼ 36.7%	2.43M▼ 42.0%	8.55M▲ 252.4%
Asset Turnover	-	-	-	-	-	-	-	-	0.05x
Asset Growth %	-43.32%	118.3%	30.2%	-15.9%	-9.83%	1.77%	-36.75%	-42.04%	252.43%
Total Current Liabilities	330K	300K	253K	232K	254K	231K	187K	206K	2.21M
Accounts Payable	17K	4K	253K	1K	2K	2K	2K	1K	196K
Days Payables Outstanding	-	-	-	-	730	730	730	-	159.69
Short-Term Debt	0	0	0	0	0	0	0	0	138K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	18K
Other Current Liabilities	0	0	0	0	0	0	0	0	1.33M
Current Ratio	8.35x	20.69x	32.39x	29.44x	24.10x	27.00x	20.35x	9.93x	0.61x
Quick Ratio	7.95x	20.40x	32.39x	29.44x	24.10x	27.00x	20.35x	9.93x	0.61x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities	0	2.67M	0	465K	2.64M	1.05M	0	0	908K
Long-Term Debt	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	219K
Other Non-Current Liabilities	0	2.67M	0	465K	2.64M	1.05M	0	0	689K
Total Liabilities	330K	2.97M	253K	232K	254K	1.28M	187K	206K	3.12M
Total Debt	0	0	0	0	0	0	0	0	138K
Net Debt	-2.02M	-3.29M	-3.25M	-4.46M	-3.63M	-2.97M	-2.09M	-1.4M	-233K
Debt / Equity	-	-	-	-	-	-	-	-	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-155.75x	-113.29x	-29.03x	-55.77x	-49.10x	-80.01x	-191.30x	-13.13x
Total Equity	2.69M▲ 0%	3.62M▲ 34.7%	8.32M▲ 130.0%	6.98M▼ 16.1%	6.25M▼ 10.5%	5.33M▼ 14.7%	4M▼ 25.0%	2.22M▼ 44.5%	5.43M▲ 144.8%
Equity Growth %	-45.02%	34.69%	129.95%	-16.13%	-10.47%	-14.66%	-25.01%	-44.49%	144.82%
Book Value per Share	62.75	49.26	103.58	86.88	77.78	55.45	46.97	26.07	49.40
Total Shareholders' Equity	2.69M	3.62M	8.32M	6.98M	3.61M	5.33M	4M	2.22M	5.43M
Common Stock	6.62M	13.18M	13.18M	13.18M	13.18M	14.12M	14.12M	14.12M	23.14M
Retained Earnings	-154.9M	-155.65M	-152.59M	-153.93M	-155.6M	-155.13M	-156.47M	-158.25M	-159.01M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	183K	67K	20K	20K	20K	20K	20K	20K	20K
Minority Interest	0	0	0	0	0	0	0	0	0

XTLB Cash Flow Statement

XTL Biopharmaceuticals Ltd. (XTLB) cash flow — operating, investing & free cash flow history

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24
Cash from Operations	-1.73M	-1.13M	-816K	-908K	-850K	-1.05M	-901K	-707K	-1.62M
Operating CF Margin %	-	-	-	-	-	-	-	-	-358.76%
Operating CF Growth %	6.93%	35.05%	27.47%	-11.27%	6.39%	-23.41%	14.11%	21.53%	-128.85%
Net Income	-2.54M	-781K	2.99M	-1.35M	-2.95M	435K	-1.35M	-1.78M	-1.03M
Depreciation & Amortization	3K	1K	0	0	1K	1K	1K	0	199K
Stock-Based Compensation	182K	40K	24K	5K	51K	37K	14K	3K	264K
Deferred Taxes	-182K	-755K	0	0	0	0	487K	0	-130K
Other Non-Cash Items	848K	-437K	-3.82M	484K	2.01M	-1.47M	-36K	1.01M	-1.11M
Working Capital Changes	-220K	52K	-8K	-50K	45K	-54K	-19K	64K	189K
Change in Receivables	-114	0	0	0	0	0	0	0	39K
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	-101K	-13K	-47K	-21K	22K	-23K	-44K	19K	208K
Cash from Investing	-66K	-2.5M	778K	2.11M	32K	8K	36K	41K	-844K
Capital Expenditures	-66K	0	0	-2K	-1K	0	0	0	-54K
CapEx % of Revenue	-	-	-	-	-	-	-	-	11.97%
Acquisitions	0	0	0	0	0	0	0	0	-410K
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-64K	5K	74K	93K	33K	8K	36K	41K	-366K
Cash from Financing	0	4.89M	0	0	0	385K	0	0	1.45M
Debt Issued (Net)	0	0	0	0	0	0	0	0	-13K
Equity Issued (Net)	0	4.89M	0	0	0	385K	0	0	1.46M
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0
Other Financing	0	0	0	0	0	0	0	0	0
Net Change in Cash	-1.8M▲ 0%	1.27M▲ 170.6%	-34K▼ 102.7%	1.2M▲ 3629.4%	-824K▼ 168.7%	-662K▲ 19.7%	-875K▼ 32.2%	-693K▲ 20.8%	-1.03M▼ 48.6%
Free Cash Flow	-1.8M▲ 0%	-1.13M▲ 37.4%	-816K▲ 27.5%	-910K▼ 11.5%	-851K▲ 6.5%	-1.05M▼ 23.3%	-901K▲ 14.1%	-707K▲ 21.5%	-1.67M▼ 136.5%
FCF Margin %	-	-	-	-	-	-	-	-	-370.73%
FCF Growth %	6.69%	37.43%	27.47%	-11.52%	6.48%	-23.27%	14.11%	21.53%	-136.49%
FCF per Share	-41.99	-15.31	-10.16	-11.33	-10.59	-10.91	-10.58	-8.30	-15.20
FCF Conversion (FCF/Net Income)	0.68x	1.44x	-0.27x	0.67x	1.09x	-2.41x	0.67x	396.75x	1.58x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

XTLB Key Ratios

XTL Biopharmaceuticals Ltd. (XTLB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-90.13%	-67.2%	-24.77%	50.01%	-17.61%	-11.82%	7.51%	-28.89%	-0.06%	-26.83%
Return on Invested Capital (ROIC)	-150.88%	-221.03%	-187.27%	-22.04%	-16.64%	-27.65%	-31.04%	-30.92%	-42.13%	-54.11%
Gross Margin	-	-	-	-	-	-	-	-	-	0.67%
Net Margin	-	-	-	-	-	-	-	-	-	-227.72%
Debt / Equity	-	-	-	-	-	-	-	-	-	0.03x
Interest Coverage	-	-	-155.75x	-113.29x	-29.03x	-55.77x	-49.10x	-80.01x	-191.30x	-13.13x
FCF Conversion	0.43x	0.68x	1.44x	-0.27x	0.67x	1.09x	-2.41x	0.67x	396.75x	1.58x

XTLB Frequently Asked Questions

XTL Biopharmaceuticals Ltd. (XTLB) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

XTL Biopharmaceuticals Ltd. (XTLB) reported $0.5M in revenue for fiscal year 2024.

XTL Biopharmaceuticals Ltd. (XTLB) grew revenue by 0.0% over the past year. Growth has been modest.

XTL Biopharmaceuticals Ltd. (XTLB) reported a net loss of $1.0M for fiscal year 2024.

Dividend & Returns

XTL Biopharmaceuticals Ltd. (XTLB) has a return on equity (ROE) of -26.8%. Negative ROE indicates the company is unprofitable.

XTL Biopharmaceuticals Ltd. (XTLB) had negative free cash flow of $1.7M in fiscal year 2024, likely due to heavy capital investments.

Explore More XTLB

XTL Biopharmaceuticals Ltd. (XTLB) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

XTL Biopharmaceuticals Ltd.(XTLB)Earnings, Financials & Key Ratios

XTLB Key Insights

✓Strengths

✗Weaknesses

XTLB Price & Volume

XTLB Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

XTLB Peer Comparison

Compare XTLB vs Peers

vs NRXP

vs MEDP

Compare Top 5

XTLB Income Statement

XTLB Balance Sheet

XTLB Cash Flow Statement

XTLB Key Ratios

XTLB Frequently Asked Questions

Explore More XTLB

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation